Skip to content
Nonprofiteer
← FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC

Form 990 for tax year 2023

Filed by FOUNDATION FOR THE NATIONAL INSTITUTE OF HEALTH INC.

Totals

Total revenue
$60,965,788
Total expenses
$69,644,743
Contributions and grants received
$56,092,197
Grants paid
$20,270,897
Program service revenue
$50,000
Investment income
$4,762,392
Other revenue
$61,199
Total assets, end of year
$206,113,368
Total liabilities, end of year
$12,576,790
Net assets or fund balances, end of year
$193,536,578
Program services expenses (Part IX)
$59,604,715
Management and general expenses
$9,821,720
Fundraising expenses
$218,308
Program service expenses (Part III)
$59,604,715

Program services were 85.6% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $333,929

  • 1e · Government grants (contributions)

    $1,250,000

  • 1f · All other contributions, gifts and grants

    $54,508,268

  • 1g · Noncash contributions included above

    $6,019,419

  • 2a · Program service revenue: Administrative Revenue

    total $50,000 · related or exempt $50,000

  • 2f · All other program service revenue

    total $0 · related or exempt $0 · unrelated business $0 · excluded $0

  • 3 · Investment income

    total $4,421,167 · excluded $4,421,167

  • 6c · Rental income or loss

    real property $0 · personal property $0

  • 7a · Gross sales of assets other than inventory

    securities $241,379,578

  • 7b · Less cost or other basis and sales expenses

    securities $241,038,353

  • 7c · Gain or loss

    securities $341,225 · other assets $0

  • 7d · Net gain or loss

    total $341,225 · excluded $341,225

  • 8a · Fundraising events: gross income

    $571,531

  • 8a · Fundraising events: contributions included on line 1c

    $333,929

  • 8b · Fundraising events: direct expenses

    $510,332

  • 8c · Net income from fundraising events

    total $61,199 · excluded $61,199

  • 11d · All other revenue

    total $0 · related or exempt $0 · unrelated business $0 · excluded $0

  • 11e · Other revenue, total

    $0

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $19,846,427 · program services $19,846,427

  • 2 · Grants to domestic individuals

    total $402,500 · program services $402,500

  • 3 · Grants to foreign organizations and individuals

    total $21,970 · program services $21,970

  • 5 · Compensation of officers, directors and key employees

    total $3,130,688 · program services $844,776 · management and general $2,285,912

  • 7 · Other salaries and wages

    total $9,734,008 · program services $6,558,766 · management and general $3,138,422 · fundraising $36,820

  • 8 · Pension plan contributions

    total $583,866 · program services $330,553 · management and general $242,375 · fundraising $10,938

  • 9 · Other employee benefits

    total $2,107,570 · program services $1,277,093 · management and general $785,497 · fundraising $44,980

  • 10 · Payroll taxes

    total $909,183 · program services $442,389 · management and general $466,794

  • 11b · Fees: legal

    total $402,168 · program services $323,560 · management and general $72,647 · fundraising $5,961

  • 11c · Fees: accounting

    total $119,100 · program services $17,325 · management and general $101,775

  • 11f · Fees: investment management

    total $202,355 · management and general $202,355

  • 11g · Fees: other

    total $0 · program services $0 · management and general $0 · fundraising $0

  • 12 · Advertising and promotion

    total $91,619 · program services $87,280 · management and general $3,868 · fundraising $471

  • 13 · Office expenses

    total $53,990 · program services $4,411 · management and general $49,579

  • 14 · Information technology

    total $178,584 · program services $57,476 · management and general $118,585 · fundraising $2,523

  • 16 · Occupancy

    total $735,836 · program services $181,754 · management and general $554,082

  • 17 · Travel

    total $2,172,051 · program services $1,860,586 · management and general $242,530 · fundraising $68,935

  • 22 · Depreciation, depletion and amortization

    total $214,733 · management and general $214,733

  • 23 · Insurance

    total $241,927 · program services $131,491 · management and general $110,436

  • 24a · Other expenses: Program Contracts

    total $22,630,837 · program services $22,621,565 · management and general $9,272

  • 24b · Other expenses: Consultants

    total $5,085,754 · program services $4,117,010 · management and general $925,735 · fundraising $43,009

  • 24c · Other expenses: Bad Debt Expense

    total $868,750 · program services $868,750

  • 24d · Other expenses: Recruiting

    total $246,367 · program services $96,050 · management and general $150,317

  • 24e · All other expenses

    total -$335,540 · program services -$487,017 · management and general $146,806 · fundraising $4,671

Balance sheet

Part X, book values.

  • 2 · Savings and temporary cash investments

    beginning of year $73,162,269 · end of year $33,349,260

  • 3 · Pledges and grants receivable

    beginning of year $49,795,550 · end of year $42,017,805

  • 5 · Loans and receivables from officers and key people

    end of year $0

  • 6 · Loans and receivables from disqualified persons

    end of year $0

  • 9 · Prepaid expenses and deferred charges

    beginning of year $255,982 · end of year $366,589

  • 10a · Land, buildings and equipment: cost or other basis

    $3,158,809

  • 10b · Land, buildings and equipment: accumulated depreciation

    $1,688,166

  • 10c · Land, buildings and equipment, net

    beginning of year $1,571,232 · end of year $1,470,643

  • 11 · Investments: publicly traded securities

    beginning of year $84,510,224 · end of year $120,900,511

  • 12 · Investments: other securities

    beginning of year $0

  • 13 · Investments: program-related

    beginning of year $0

  • 15 · Other assets

    beginning of year $7,287,285 · end of year $8,008,560

  • 17 · Accounts payable and accrued expenses

    beginning of year $8,918,557 · end of year $4,105,123

  • 19 · Deferred revenue

    beginning of year $783,334 · end of year $408,334

  • 22 · Loans and payables to officers and key people

    end of year $0

  • 25 · Other liabilities

    beginning of year $8,553,216 · end of year $8,063,333

  • 27 · Net assets without donor restrictions

    beginning of year $27,430,780 · end of year $32,672,601

  • 28 · Net assets with donor restrictions

    beginning of year $170,896,655 · end of year $160,863,977

Mission and programs · 2023

Mission

See Schedule O, Statement of Organization's Primary Exempt Purpose Statement To create and lead alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people's lives

Activities or mission (Part I)

The Foundation for the National Institutes of Health (FNIH) builds public-private partnerships that connect leading biomedical scientists at the National Institutes of Health (NIH) with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies (including the Food and Drug Administration and European Medicines Agency). Through team science, the FNIH solves complex health challenges and accelerates breakthroughs for patients, regardless of who they are or what health threats they face. The FNIH contributes to the development of new therapies, diagnostics, and potential cures; advances global health and equity in care; and celebrates and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. For more information about the FNIH, please visitfnih.org.

  • SEE SCHEDULE O, PROGRAM ONE, RESEARCH PROGRAMS New Public-Private Partnership Supports Development of Pediatric Medical Devices Despite efforts to support innovation in pediatric medical devices, challenges remain in developing these technologies for children, including concerns about device longevity and long-term exposure to implanted materials. The FNIH announced the launch of a project design phase to address the gap in availability of these devices. The project is supported by a public-private partnership between the NIH, the U.S. Food and Drug Administration, the Biomedical Advanced Research and Development Authority, and partners from the private sector. A full-scale pediatric medical device public-private partnership project will follow the design phase, with the goal of developing a sustainable infrastructure for creating and commercializing these devices. STRENGTHENING THE PATIENT VOICE The FNIH puts patients first. When their perspectives are incorporated into our work, the result will be faster medical breakthroughs for some of today's most pressing health challenges. To do this, we work closely with our Patient Ambassadors, made up of people with lived experience of a disease, and our Patient Engagement Council, comprised of representatives of patient-centric organizations. The Council convened its first Patient Summit in 2023. Six Patient Ambassadors, ten members of the Council, and FNIH staff members who attended the day-long event identified and discussed strategies to better involve and engage people with health challenges in FNIH projects. RESEARCH PROGRAMS FOR ADVANCING GLOBAL HEALTH Award-Winning A-PLUS Study: Improving Outcomes for Laboring Women Worldwide Maternal sepsis affects an estimated 6 million women per year and is the third most commoncause of maternal mortality globally. The Azithromycin Prevention in Labor Use Study (A-PLUS), a groundbreaking multinational clinical trial, demonstrated that one dose of azithromycin, a low-cost, generic, oral antibiotic, given during labor to women planning to deliver vaginally could reduce the occurrence of life-threatening sepsis. Initial study results, published in the New England Journal of Medicine and presented at the Society for Maternal-Fetal Medicine's Pregnancy Meeting 2023, showed that azithromycin use cut the risk of maternal sepsis by 35% and could prevent up to 2 million such cases per year. Global Pandemic Treaty: FNIH Convenes, Informs Leaders The member countries of the World Health Organization (WHO) continued negotiation of a pandemic agreement to "address gaps in preventing, preparing for, and responding to health emergencies [through] a comprehensive and coherent approach to strengthen the global health architecture ... with a whole-of-government and whole-of-society approach, prioritizing the need for equity." The FNIH in 2023 continued its work to inform WHO and the global community as it considers the treaty. The FNIH, in partnership with WHO's collaborating center at Georgetown University's O'Neill Institute for National and Global Health Law, convened two high-level global consultations to provide technical advice and information on key topics identified by the WHO's Intergovernmental Negotiating Body (INB) as critical for the treaty's success. - In collaboration with UNAIDS, convened an expert group to consider existing models that assert equity as a priority and analyze them for possible inclusion in the treaty. Attendees included: INB Co-Chair Precious Matsoso and senior WHO observers assisting the INB. Report of the convening: Advancing a World Together Equitably - In collaboration with the University of Cape Town, organized a global meeting on the development and deployment of emergency countermeasures, including vaccines, diagnostics, and treatments. The expert group examined case studies for countermeasure development, pandemic clinical trial capabilities, and access and benefit sharing. Report of the convening: Emergency Countermeasure Development and Deployment Thought pieces providing insights into pandemic preparedness were published in Hastings Center Reports and Health Affairs Forefront.

    Expenses $58,235,139 · Grants $19,658,554 · Revenue $50,000

  • Withheld by Nonprofiteer: this text may name a private individual.

    Expenses $1,369,576 · Grants $612,343

As filed on the 2023 return. A text marked withheld matched a screen for wording that may name a private individual, such as an honorific or "in memory of". Most of what it withholds names no one; it is withheld so that what does is never shown.

Listed in Part VII

  • Dr Julie L Gerberding

    Chief Executive Officer

    Total calculated
    $657,029
    From this org
    $613,755
    From related orgs
    $0
    Other
    $43,274
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $513,755
    Bonus
    $100,000
    Other
    $0
    Deferred
    $26,400
    Nontaxable benefits
    $16,874
    Filer's total
    $657,029

  • Charles A Reinhart III

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Dame Jillian Sackler

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Dr Charles A Sanders

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Dr Edison T Liu

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Dr Elias Zerhouni

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Dr Ellen V Sigal

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Dr Freda Lewis-Hall

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Dr Judy Lansing Kovler

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Dr Paul Stoffels

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Dr Ronald L Krall

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Dr Solomon H Snyder

    Vice-Chairman

    Total calculated
    $0
    Hours/week
    0.5

  • Dr Steven M Paul

    Chairman

    Total calculated
    $0
    Hours/week
    1.5

  • Gilbert S Omenn

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • James Weiss

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Jay Bradner

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Mr Fred Seigel

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Mr James H Donovan

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Mr Russell W Steenberg

    Board Member

    Total calculated
    $0
    Hours/week
    0.5

  • Mrs William McCormick Blair Jr

    Secretary

    Total calculated
    $0
    Hours/week
    1

  • Ms Julie Bell Lindsay

    Treasurer

    Total calculated
    $0
    Hours/week
    2

  • David Carmel

    Senior Vice President, Chief Growth and Innovation Officer

    Total calculated
    $441,135
    From this org
    $400,911
    From related orgs
    $0
    Other
    $40,224
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $397,411
    Bonus
    $3,500
    Other
    $0
    Deferred
    $26,400
    Nontaxable benefits
    $13,824
    Filer's total
    $441,135

  • David Wholley

    Chief Strategy and Business Development (UNTIL NOV.)

    Total calculated
    $415,411
    From this org
    $375,609
    From related orgs
    $0
    Other
    $39,802
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $312,942
    Bonus
    $25,250
    Other
    $37,417
    Deferred
    $26,400
    Nontaxable benefits
    $13,402
    Filer's total
    $415,411

  • Donald Hill

    Senior Vice President, Chief Financial Officer

    Total calculated
    $329,559
    From this org
    $289,166
    From related orgs
    $0
    Other
    $40,393
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $279,166
    Bonus
    $10,000
    Other
    $0
    Deferred
    $23,519
    Nontaxable benefits
    $16,874
    Filer's total
    $329,559

  • Joseph Menetski

    Senior Vice President, Chief Translational Science Officer

    Total calculated
    $364,635
    From this org
    $324,692
    From related orgs
    $0
    Other
    $39,943
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $314,692
    Bonus
    $10,000
    Other
    $0
    Deferred
    $26,119
    Nontaxable benefits
    $13,824
    Filer's total
    $364,635

  • Julie Wolf Rodda

    Chief Strategic Alliances and Advancement Officer (UNTIL NOV.)

    Total calculated
    $198,446
    From this org
    $180,943
    From related orgs
    $0
    Other
    $17,503
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $126,016
    Bonus
    $10,000
    Other
    $44,927
    Deferred
    $11,005
    Nontaxable benefits
    $6,498
    Filer's total
    $198,446

  • Kevin Klock

    Senior Vice President, Chief Operating Officer and General Counsel

    Total calculated
    $321,315
    From this org
    $283,492
    From related orgs
    $0
    Other
    $37,823
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $273,492
    Bonus
    $10,000
    Other
    $0
    Deferred
    $22,999
    Nontaxable benefits
    $14,824
    Filer's total
    $321,315

  • Michael Santos

    Senior Vice President, Chief Population Health Science Officer

    Total calculated
    $403,158
    From this org
    $368,742
    From related orgs
    $0
    Other
    $34,416
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $358,742
    Bonus
    $10,000
    Other
    $0
    Deferred
    $26,400
    Nontaxable benefits
    $8,016
    Filer's total
    $403,158

  • Courtney Silverthorn

    Associate Vice President, Science Partnerships Translational Science

    Total calculated
    $263,633
    From this org
    $236,430
    From related orgs
    $0
    Other
    $27,203
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $227,930
    Bonus
    $8,500
    Other
    $0
    Deferred
    $18,927
    Nontaxable benefits
    $8,276
    Filer's total
    $263,633

  • Eva Coyne

    Vice President -Controller

    Total calculated
    $263,970
    From this org
    $231,174
    From related orgs
    $0
    Other
    $32,796
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $223,374
    Bonus
    $7,800
    Other
    $0
    Deferred
    $18,743
    Nontaxable benefits
    $14,053
    Filer's total
    $263,970

  • Robert Balthaser

    Vice President of Advancement (UNTIL NOV.)

    Total calculated
    $240,611
    From this org
    $220,316
    From related orgs
    $0
    Other
    $20,295
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $161,737
    Bonus
    $2,500
    Other
    $56,079
    Deferred
    $13,092
    Nontaxable benefits
    $7,203
    Filer's total
    $240,611

  • Stacey Adam

    Associate Vice President, Science Partnerships Translational Science

    Total calculated
    $286,763
    From this org
    $258,208
    From related orgs
    $0
    Other
    $28,555
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $243,208
    Bonus
    $15,000
    Other
    $0
    Deferred
    $20,639
    Nontaxable benefits
    $7,916
    Filer's total
    $286,763

  • Steven Hoffmann

    Associate Vice President, Science Partnerships Translational Science

    Total calculated
    $273,271
    From this org
    $240,048
    From related orgs
    $0
    Other
    $33,223
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $230,048
    Bonus
    $10,000
    Other
    $0
    Deferred
    $19,399
    Nontaxable benefits
    $13,824
    Filer's total
    $273,271

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Independent compensation consultant
  • 3 · Written employment contract
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Provenance

Return type
form_990
Tax year
2023
Filed
13 November 2024
IRS schema version
2023v5.1
Source object
202443189349301314

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.